EUVIMEDObjevte EUVIMED
Open access

Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21

Shiyi Yu iD, Xue Gong iD, Yawen Yang iD, Ying Duan iD, Siyu Zhang iD, Ying Wang, Zheng Wang, Caili Bi iD, Haibo Sun iD

Science Advances · 2026

DOI: 10.1126/sciadv.aea2001 ↗

At a glance

Journal article in Science Advances, 2026. Written by Shiyi Yu and 8 co-authors. Institution: School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucl…. Major MEDLINE topics: Drug Resistance, Neoplasm, Exons, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. 87 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Government of Jiangsu Province, Yangzhou University.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard therapies for estrogen receptor–positive breast cancer, but their efficacy is limited by drug resistance. While dysregulation of alternative splicing has been implicated in cancer progression, the underlying mechanisms remain unclear. Here, we uncover a splicing-mediated mechanism whereby exon 2 inclusion in SUV39H2 drives its overexpression in CDK4/6i-resistant breast cancer cells. Clinically, elevated exon 2 inclusion in SUV39H2 correlates with poor prognosis in patients with breast cancer. Targeting SUV39H2 with gapmer antisense oligonucleotides or a methyltransferase inhibitor overcomes CDK4/6i resistance and reinstates therapy-induced senescence in breast cancer cells by reducing SUV39H2 expression or activity. Mechanistically, targeting SUV39H2 promotes transcriptional activation of senescence-associated secretory phenotype genes, including p21 , through H3K9me3 removal at enhancer regions and subsequent chromatin opening at promoters. Our work unveils a splicing-mediated resistance mechanism and presents a potential synergistic drug target for CDK4/6i therapy.

Subjects

MeSH terms (MEDLINE)

Drug Resistance, NeoplasmExonsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Transcriptional ActivationHistone-Lysine N-MethyltransferaseCyclin-Dependent Kinase Inhibitor p21Protein Kinase InhibitorsBreast NeoplasmsHumansCell Line, TumorGene Expression Regulation, NeoplasticFemaleAlternative SplicingCellular Senescence

Substances

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Histone-Lysine N-MethyltransferaseCyclin-Dependent Kinase Inhibitor p21Protein Kinase InhibitorsCDK4 protein, humanCDK6 protein, human

Authors and institutions

  • School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangs…
  • School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Integrated Traditional Chinese and Western Medicine in Senile Diseases Con…
  • Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.
  • Nanjing Women and Children's Healthcare Institute, Women's Hospital of Nanjing Medical University, 123 Tianfei Alley, Mochou Road, Nanjing, Jiangsu 210004, PR China.
  • Department of Thyroid and Breast Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.
  • Department of Pathology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.

ORCID profiles: Shiyi Yu, Xue Gong, Yawen Yang, Ying Duan, Siyu Zhang, Caili Bi, Haibo Sun

Funding

  • National Natural Science Foundation of China
  • Government of Jiangsu Province
  • Yangzhou University
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Natural Science Foundation of the Jiangsu Higher Education Institutions
  • Nanjing Medical Science and Technology Development Foundation
  • Distinguished Doctoral Program of Green Yang Golden Phoenix of Yangzhou City

Cite

APA

Yu, S., Gong, X., Yang, Y., Duan, Y., Zhang, S., Wang, Y., Wang, Z., Bi, C., & Sun, H. (2026). Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science Advances. https://doi.org/10.1126/sciadv.aea2001

Vancouver

Yu S, Gong X, Yang Y, Duan Y, Zhang S, Wang Y, et al. Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science Advances. 2026. doi:10.1126/sciadv.aea2001

BibTeX
@article{Yu2026,
  author = {Yu, Shiyi and Gong, Xue and Yang, Yawen and Duan, Ying and Zhang, Siyu and Wang, Ying and Wang, Zheng and Bi, Caili and Sun, Haibo},
  title = {Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aea2001}
}
Start for free →